Prokidney Corp. (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$1.95
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.95
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.54 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)795.66K
Market Cap
$588.74M
Enterprise Value$458.98M
Total Cash (Recent Filing)$270.02M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
May 08, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding141,942,900
10 Day Avg. Volume892,808
30 Day Avg. Volume795,663
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue513.98
Enterprise Value/Gross Profit-234.89
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$7.33Price Target Upside275.90% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$216.67K
Bulls Say, Bears Say
Bulls Say
Accelerated Approval PathwayRegulatory alignment to pursue an FDA‑aligned accelerated approval pathway using the eGFR slope as a surrogate endpoint reduces regulatory uncertainty and could enable a faster route to market if surrogate results meet regulatory thresholds.
Favorable Prior Data And Safety ProfilePositive Phase 2 results showing improved kidney function after bilateral injection, combined with no procedure‑ or product‑related serious adverse events, strengthen the clinical rationale and safety profile for the therapy.
Trial Enrollment MomentumStrong and unusually high patient enrollment for the pivotal cell therapy trial indicates robust patient and physician interest, lowering execution risk and supporting timely completion of study milestones.
Bears Say
Confirmatory Timeline ExtensionKeeping the same number of required events while reducing total confirmatory enrollment implies the confirmatory analysis will take longer to complete, extending uncertainty around final approval timing.
Reduced Confirmatory EnrollmentReducing confirmatory study enrollment while maintaining the same statistical assumptions concentrates events and increases the risk that slower event accrual will delay the confirmatory outcome.
Surrogate Endpoint Regulatory RiskDependence on meeting the eGFR slope surrogate endpoint for regulatory approval creates outcome and regulatory risk if the pivotal trial fails to achieve the required surrogate threshold.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.54 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $588.74M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is May 08, 2026 which is in 26 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Mar 18, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.007.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 141,942,900 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.33 (275.90% Upside)
$7.33 (275.90% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
218.10%
12-Months-Change
Fundamentals
Return on Equity
6.86%
Trailing 12-Months
Asset Growth
-24.10%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$7.33
▲(275.90% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---